Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia | Zendy

Heidi Taipale | Zendy; Antti Tanskanen | Zendy; Jurjen J. Luykx | Zendy; Marco Solmi | Zendy; Stefan Leucht | Zendy; Christoph U. Correll | Zendy; Jari Tiihonen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia

Author(s) -

Heidi Taipale,

Antti Tanskanen,

Jurjen J. Luykx,

Marco Solmi,

Stefan Leucht,

Christoph U. Correll,

Jari Tiihonen

Publication year - 2022

Publication title -

schizophrenia bulletin

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.823

H-Index - 190

eISSN - 1745-1707

pISSN - 0586-7614

DOI - 10.1093/schbul/sbac039

Subject(s) - perphenazine , olanzapine , risperidone , medicine , antipsychotic , cohort , schizophrenia (object oriented programming) , hazard ratio , psychiatry , defined daily dose , confidence interval , drug

Optimal doses of most antipsychotics in the maintenance treatment of schizophrenia are unknown. We aimed to study the risk of severe relapse indicated by rehospitalization for different dose categories of 15 most frequently used antipsychotics in monotherapy in Finland.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research